It is our view that, at this point in time, the most efficient and appropriate strategy is that of clinically targeted analysis, using one of the benchtop sequencers discussed previously, rather than whole-exome sequencing or whole-genome sequencing, such that only genes of relevance to the specific condition are analyzed and the results of which are shared with patients. That is not to say that such new tests will focus only on a single gene but, rather, that all possible known causal genes with the potential to cause a condition will be screened. For example, in the case of PD, a targeted test that screens all possible causal Mendelian genes could include the following typical set: SNCA, LRRK2, PARK2, PARK7, PINK1, and VPS35. However, one would probably wish to include genes that have been associated with other atypical forms of parkinsonism such as ATP13A2, FBX07, and PLA2G6 and genes such as MAPT and GCH1 associated with phenocopies of PD. Thus, in this case, a specific diagnostic question is whether to “test” the genome sequence for known clinically validated pathogenic variants.